Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Yi-Long Wu, Margarita Majem, Thomas John, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lu, Frances A. Shepherd, Qun Wang, Terufumi Kato, Keiju Aokage, Wen-Zhao Zhong, Konstantin Laktionov, Ming-Fang Wu, Charuwan Akewanlop, Huu Vinh Vu, Ki Hyeong Lee, Xiangning Huang, Elena Armenteros-Monterroso, Yuri Rukazenkov, Roy S. Herbst

Open source

DOI: 10.1016/j.jtho.2026.104179
Published: 2026-09
Container: Journal of Thoracic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2026.104179,
  title = {Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]},
  author = {Yi-Long Wu and Margarita Majem and Thomas John and Christian Grohé and Jie Wang and Jonathan W. Goldman and Shun Lu and Frances A. Shepherd and Qun Wang and Terufumi Kato and Keiju Aokage and Wen-Zhao Zhong and Konstantin Laktionov and Ming-Fang Wu and Charuwan Akewanlop and Huu Vinh Vu and Ki Hyeong Lee and Xiangning Huang and Elena Armenteros-Monterroso and Yuri Rukazenkov and Roy S. Herbst},
  year = {2026},
  journal = {Journal of Thoracic Oncology},
  doi = {10.1016/j.jtho.2026.104179},
  url = {https://doi.org/10.1016/j.jtho.2026.104179}
}

RIS

TY  - JOUR
TI  - Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]
AU  - Yi-Long Wu
AU  - Margarita Majem
AU  - Thomas John
AU  - Christian Grohé
AU  - Jie Wang
AU  - Jonathan W. Goldman
AU  - Shun Lu
AU  - Frances A. Shepherd
AU  - Qun Wang
AU  - Terufumi Kato
AU  - Keiju Aokage
AU  - Wen-Zhao Zhong
AU  - Konstantin Laktionov
AU  - Ming-Fang Wu
AU  - Charuwan Akewanlop
AU  - Huu Vinh Vu
AU  - Ki Hyeong Lee
AU  - Xiangning Huang
AU  - Elena Armenteros-Monterroso
AU  - Yuri Rukazenkov
AU  - Roy S. Herbst
PY  - 2026
JO  - Journal of Thoracic Oncology
DO  - 10.1016/j.jtho.2026.104179
UR  - https://doi.org/10.1016/j.jtho.2026.104179
ER  -

APA

Wu, Y., Majem, M., John, T., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Shepherd, F. A., Wang, Q., Kato, T., Aokage, K., Zhong, W., Laktionov, K., Wu, M., Akewanlop, C., Vu, H. V., Lee, K. H., Huang, X., Armenteros-Monterroso, E., Rukazenkov, Y., & Herbst, R. S. (2026). Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2026.104179

Source records

crossref · retrieved 2026-09-25T12:12:43.453Z